Efficacy of low-dose lansoprazole in the treatment of non-erosive gastroesophageal reflux disease. Influence of infection by Helicobacter pylori;Eficacia de lansoprazol a dosis bajas en el tratamiento de la enfermedad por reflujo gastroesofágico no erosiva. Influencia de la infección por Helicobacter pylori

Revista Espanola de Enfermedades Digestivas

Volumn 98, Issue 3, 2006, Pages 170-179

  Castro Fernández, Manuel ^a   Garcia Diaz E ^a   Larraona, J L ^a   Rodriguez Hornillo M C ^a   Lamas Rojas, E ^a   Nunez Hospital D ^a   Pallares Querol M ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Helicobacter pylori; Lansoprazole; Non erosive reflux disease

Indexed keywords

LANSOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; OMEPRAZOLE; PROTON PUMP;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH BIOPSY; DRUG ANTAGONISM; HELICOBACTER PYLORI; MIDDLE AGED; PILOT STUDY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PILOT PROJECTS; PROTON PUMPS; SINGLE-BLIND METHOD;

EID: 33745565392     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082006000300003     Document Type: Article

References (41)

1. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Supl.): S2-S7.
2. Ofman JJ, The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Supl.): S8-S14.
3. Buttar NS, Faik GW. Pathogenesis of gastroesophageal reflux and Barret esophagus. Mayo Clin Proc 2001; 76: 226-34.
4. Wong WM, Wong BCY. Definition and diagnosis of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19 (Supl. 3): S26-32.
5. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19 (Supl. 1): 28-34.
6. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885-92.
7. Kahrilas PJ. Diagnostic of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Supl.): S15-S23.
8. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Sugested disease management guidelines. Arch Intern Med 1996; 156: 477-84.
9. Hillman AL, Bloom BS, Fendrich AM, Schwartz JS. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467-72.
10. Manzionna G, Pace F, Porro B. Efficacy of lansoprazole in the shortand long-term treatment of gastro-oesophageal reflux disease. Clin Drug Invest 1997; 14: 450-6.
11. Benhaim MC, Evereux M, Salducci J, Petite JP, Lemaire M. Lansoprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Gastroenterology 1990: 98: A20 (Abstract).
12. Castell Do, Ritcher JE, Robinson M, Sontang SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57.
13. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 859-67.
14. Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S; Italian Lansoprazole Study Group. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002; 97: 1357-64.
15. Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R. Lanzoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999; 13: 795-804.
16. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803-9.
17. Raghunath AS, Hungin APS, Woof D, Childs S. Systematic review: The effect of Helicobacter pylori ands its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733-44.
18. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter Project. BMJ 2004; 328: 1417-9.
19. Guliter S, Kandilci U. The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. J Clin Gastroenterol 2004; 38: 750-5.
20. Beales IL. Helicobacter pylori and gastro-oesophageal reflux disease: important data were not presented. BMJ 2004; 329: 402.
21. O'Connor HJ. Review article: Helicobater pylori and gastroesophageal reflux disease. Clinical implication and manegement. Aliment Pharmacol Ther 1999; 13: 17-27.
22. Wu JC, Sung JJ, Ng EK, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a estudy from the East. Am J Gastroenterol 1999; 94: 1790-4.
23. McColl KE. Review article: Helicobacter pylori and gastroesophageal reflux disease: The European perspective. Aliment Pharmacol Ther 2004; 20 (Supl. 8): 36-9.
24. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cag A-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
25. Fallone CA, Barkun AN, Mayrand S, et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004; 20: 761-8.
26. Malfertheiner P, Gerards C. Helicobacter pylori infection and gastro-oesophageal reflux disease: coincidence or association? Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 731-41.
27. McKoll KE. Motion-Helicobacter pylori causes or worsens GERD: arguments against the motion. Can J Gastroenterol 2002; 16: 615-7.
28. O'Morain CA, Qasim A. Motion-Helicobacter pylori worsens GERD: arguments for the motion. Can J Gastroenterol 2002; 16: 611-4.
29. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-89.
30. Garrido Serrano A, Lepe Jiménez JA, Guerrero Igea FJ, Perianes Hernández C. Helicobacter pylori and gastroesophageal reflux disease. Rev Esp Enferm Dig 2003; 95: 788-90.
31. Gisbert JP, de Pedro A, Losa C, Barreiro A, Pajares JM. Helicobacter pylori and gastroesophageal reflux disease: lack of influence of infection on twenty-four hour esophageal ph monitoring and endoscopic findings. J Clin Gastroenterol 2001; 32: 210-4.
32. Martinek J, Kuzela L, Spicak J, Vavrecka A. Review article: the clinical influence of Helicobacter pylori in effective acid suppression-implications for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 979-90.
33. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003; 17: 297-305.
34. Quigley EMM. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Supl.): S24-S30.
35. Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
36. Gerards C, Leodolter A, Glasbrenner B, Malfertheiner P. H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Dis Dis 2001; 19: 170-3.
37. Zarate-López N. Helicobacter pylori en la GORD: ser o no ser. Gastroenterol Hepatol (Monog) 2003; 1: 18-24.
38. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003; 98 (Supl.): S31-S39.
39. McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease how well do clinicians'assessements agree with those of their patients? Am J Gastroenterol 2005; 100: 11-8.
40. Earnest DL, Dorsch E, Jones J, et al. A placebo-controlled dose -ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238-43.
41. Boixeda D, Gisbert JP, Cantón R, Álvarez Baleriola I, Gil Grande LA, Martín de Argila C. ¿Existe alguna relación entre la infección por Helicobacter pylori y la esofagitis péptica? Med Clin (Barc) 1995; 105: 774-7.